CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA CuraTeQ Biologics receives approval for Biosimilar Zefylti from the UK’s MHRA The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share. DSIJ Intelligence-1 / Wednesday, May 14, 2025 / Article rating: 5.0 The company has a market cap of over Rs 70,000 crore and the stock is up by 24.3 per cent from its 52-week low of Rs 994.35 per share.
Eugia Pharma receives USFDA Approval for Dasatinib Tablets Eugia Pharma receives USFDA Approval for Dasatinib Tablets The company has a market cap of over Rs 70,000 crore and the stock is up by 23 per cent from its 52-week low of Rs 994.35 per share. DSIJ Intelligence-1 / Wednesday, April 23, 2025 / Article rating: 5.0 The company has a market cap of over Rs 70,000 crore and the stock is up by 23 per cent from its 52-week low of Rs 994.35 per share.
Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP Pharma company receives final ANDA approval for Rivaroxaban Tablets USP, 2.5mg & tentative approval for other strengths of Rivaroxaban Tablets USP Aurobindo Pharma Limited announced obtaining the last approval from the US Food & Drug Administration (USFDA) for Rivaroxaban Tablets USP, 2.5 mg. DSIJ Intelligence-1 / Monday, April 14, 2025 / Article rating: 5.0 The biosimilars division alongside niche product development represents Aurobindo Pharma's main focus areas where its 1500 scientists dedicate their efforts.